Stephen Pethen
About Stephen Pethen
Stephen Pethen serves as the Director of DMPK and Screening at KalVista Pharmaceuticals, Inc. in Salisbury, England, where he has worked since 2021, and has been a Team Leader in DMPK since 2012.
Work at KalVista Pharmaceuticals
Stephen Pethen has held the position of Director DMPK and Screening at KalVista Pharmaceuticals, Inc. since 2021. In this role, he oversees drug metabolism and pharmacokinetics (DMPK) and screening processes, contributing to the development of innovative therapies. Prior to this position, he served as Team Leader - DMPK at the same company for 12 years, starting in 2012. His extensive experience in DMPK has been instrumental in advancing the company's research and development efforts in Salisbury, England.
Previous Experience at Ferring Pharmaceuticals
Before joining KalVista Pharmaceuticals, Stephen Pethen worked at Ferring Pharmaceuticals as a Principal Scientist in ADMET from 2005 to 2008. His role involved assessing the absorption, distribution, metabolism, excretion, and toxicity (ADMET) of drug candidates. This experience contributed to his expertise in drug development and regulatory compliance within the pharmaceutical industry, particularly in Southampton, England.
Career at Covance
Stephen Pethen began his career at Covance, where he worked as a Scientist from 1994 to 2005. Over the course of 11 years, he gained significant experience in preclinical research and development. His work at Covance laid the foundation for his subsequent roles in DMPK and ADMET, enhancing his understanding of the drug development process and contributing to his professional growth in Harrogate, England.
Education and Expertise
Stephen Pethen possesses a strong educational background in the field of pharmaceutical sciences, which supports his roles in DMPK and screening. His expertise encompasses drug metabolism, pharmacokinetics, and ADMET studies, making him a valuable asset in the pharmaceutical industry. His extensive experience across various organizations has equipped him with a comprehensive understanding of drug development and regulatory requirements.